Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daclatasvir/Asunaprevir/Beclabuvir regulates innate immunity by inhibition of nonstructural 5B and suppresses liver fibrosis development

Trial Profile

Daclatasvir/Asunaprevir/Beclabuvir regulates innate immunity by inhibition of nonstructural 5B and suppresses liver fibrosis development

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs Asunaprevir/becabluvir/daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Oct 2018 Status changed from active, no longer recruiting to discontinued.
    • 17 Apr 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 04 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top